236 related articles for article (PubMed ID: 30987721)
1. Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC-MS/MS.
Lin CN; Wu IW; Huang YF; Peng SY; Huang YC; Ning HC
J Food Drug Anal; 2019 Apr; 27(2):502-509. PubMed ID: 30987721
[TBL] [Abstract][Full Text] [Related]
2. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis.
Shu C; Chen X; Xia T; Zhang F; Gao S; Chen W
Biomed Chromatogr; 2016 Nov; 30(11):1782-1788. PubMed ID: 27129599
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
[TBL] [Abstract][Full Text] [Related]
4. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients.
Rossi M; Johnson DW; Xu H; Carrero JJ; Pascoe E; French C; Campbell KL
Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):860-865. PubMed ID: 26026209
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
Lin CJ; Wu V; Wu PC; Wu CJ
PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
[TBL] [Abstract][Full Text] [Related]
6. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.
Rossi M; Campbell K; Johnson D; Stanton T; Pascoe E; Hawley C; Dimeski G; McWhinney B; Ungerer J; Isbel N
Nutr Metab Cardiovasc Dis; 2014 Sep; 24(9):1035-42. PubMed ID: 24880738
[TBL] [Abstract][Full Text] [Related]
7. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.
Holle J; Querfeld U; Kirchner M; Anninos A; Okun J; Thurn-Valsassina D; Bayazit A; Niemirska A; Canpolat N; Bulut IK; Duzova A; Anarat A; Shroff R; Bilginer Y; Caliskan S; Candan C; Harambat J; Özcakar ZB; Soylemezoglu O; Tschumi S; Habbig S; Yilmaz E; Balat A; Zurowska A; Cakar N; Kranz B; Ertan P; Melk A; Azukaitis K; Schaefer F
Pediatr Nephrol; 2019 Dec; 34(12):2571-2582. PubMed ID: 31428929
[TBL] [Abstract][Full Text] [Related]
8. Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children.
Holle J; Kirchner M; Okun J; Bayazit AK; Obrycki L; Canpolat N; Bulut IK; Azukaitis K; Duzova A; Ranchin B; Shroff R; Candan C; Oh J; Klaus G; Lugani F; Gimpel C; Büscher R; Yilmaz A; Baskin E; Erdogan H; Zaloszyc A; Özcelik G; Drozdz D; Jankauskiene A; Nobili F; Melk A; Querfeld U; Schaefer F;
PLoS One; 2020; 15(10):e0240446. PubMed ID: 33108385
[TBL] [Abstract][Full Text] [Related]
9. Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients.
Ramos CI; Armani RG; Canziani ME; Ribeiro Dolenga CJ; Nakao LS; Campbell KL; Cuppari L
J Ren Nutr; 2020 Jan; 30(1):31-35. PubMed ID: 30956092
[TBL] [Abstract][Full Text] [Related]
10. Reference ranges and biological variation of free and total serum indoxyl- and p-cresyl sulphate measured with a rapid UPLC fluorescence detection method.
Pretorius CJ; McWhinney BC; Sipinkoski B; Johnson LA; Rossi M; Campbell KL; Ungerer JP
Clin Chim Acta; 2013 Apr; 419():122-6. PubMed ID: 23428591
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease.
Prokopienko AJ; West RE; Stubbs JR; Nolin TD
J Pharm Biomed Anal; 2019 Sep; 174():618-624. PubMed ID: 31276982
[TBL] [Abstract][Full Text] [Related]
13. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients.
Boelaert J; Lynen F; Glorieux G; Eloot S; Van Landschoot M; Waterloos MA; Sandra P; Vanholder R
Anal Bioanal Chem; 2013 Feb; 405(6):1937-47. PubMed ID: 23307120
[TBL] [Abstract][Full Text] [Related]
14. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury.
André C; Bennis Y; Titeca-Beauport D; Caillard P; Cluet Y; Kamel S; Choukroun G; Maizel J; Liabeuf S; Bodeau S
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122234. PubMed ID: 32615535
[TBL] [Abstract][Full Text] [Related]
15. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease.
Summers SC; Quimby JM; Isaiah A; Suchodolski JS; Lunghofer PJ; Gustafson DL
J Vet Intern Med; 2019 Mar; 33(2):662-669. PubMed ID: 30561098
[TBL] [Abstract][Full Text] [Related]
16. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
[TBL] [Abstract][Full Text] [Related]
17. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
[TBL] [Abstract][Full Text] [Related]
18. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.
Poesen R; Viaene L; Verbeke K; Claes K; Bammens B; Sprangers B; Naesens M; Vanrenterghem Y; Kuypers D; Evenepoel P; Meijers B
Clin J Am Soc Nephrol; 2013 Sep; 8(9):1508-14. PubMed ID: 23813557
[TBL] [Abstract][Full Text] [Related]
19. Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.
Veldeman L; Vanmassenhove J; Van Biesen W; Massy ZA; Liabeuf S; Glorieux G; Vanholder R
Int Urol Nephrol; 2019 Feb; 51(2):293-302. PubMed ID: 30604232
[TBL] [Abstract][Full Text] [Related]
20. Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial.
Takkavatakarn K; Puapatanakul P; Phannajit J; Sukkumme W; Chariyavilaskul P; Sitticharoenchai P; Leelahavanichkul A; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
